Baroda BNP Paribas Health and Wellness Fund
- NAV as on 25 Sep 2026
- ₹10.77-0.45%1 day
- Return since launch
- 6.0%
- 52-week range
- ₹8.96 — ₹10.91
- AUM
- ₹507 Cr
Baroda BNP Paribas Health and Wellness Fund is a Sectoral-Pharma equity fund from Baroda BNP Paribas Mutual Fund with ₹507 Cr under management, launched in 2025. The expense ratio is 2.79% and the SEBI riskometer reading is Very High.
Performance
Baroda BNP Paribas Health and Wellness Fund NAV and returns
Growth of the fund against its category average over the period you pick.
Over 1Y this fund returned +13.7% against +19.5% for its category.
Performance
Returns
How the fund has done against its category and its benchmark.
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1Y | 20.3% | −0.6 pts | 20.9% | 26.4% |
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1M | -0.2% | −0.4 pts | 0.2% | -0.3% |
| 3M | 5.6% | −0.6 pts | 6.2% | 6.0% |
| 6M | 16.8% | −5.4 pts | 22.1% | 20.9% |
| 1Y | 13.7% | −7.1 pts | 20.9% | 19.5% |
Since launch (9 Jun 2025): 6.0%
Returns over one year are annualised. Shorter periods are absolute.
Costs & terms
Costs and terms
What the fund charges each year, and the rules around putting money in and taking it out.
Costs
2.74%
Expense ratio as on 25 Sep 2026
Charged yearly and already deducted from the NAV.
- Base expense
- 2.09%
- Brokerage
- 0.09%
- Transaction charges
- 0.01%
- Statutory levies
- 0.55%
- Exit load
- Exit Load for units in excess of 10% of the investment,1% will be charged for redemption within 1 year.
- Lock-in
- None
Terms
- Min SIP
- ₹3,000
- Min lumpsum
- ₹5,000
- Plan
- GROWTH
- Fund type
- OPEN-ENDED
- Benchmark
- BSE Healthcare TRI
- Short-term capital gains
- Returns taxed at 20% if you redeem before 1 year
- Long-term capital gains
- After 1 year, returns above ₹1.25 lakh in a financial year are taxed at 12.5%
Risk
Risk
What the riskometer means for this fund, and how its ratios sit against the category.
Your principal is treated as being at very high risk — typically small cap, sectoral and thematic equity schemes.
Portfolio
Baroda BNP Paribas Health and Wellness Fund portfolio
Portfolio as of 31 Aug 2026
Asset allocation
- Equity98.8%
- Debt1.0%
- Other0.2%
Market cap split
- Large32.8%
- Mid46.8%
- Small20.4%
- P/E
- 45.73
- P/B
- 7.16
Top holdings
| Holding | Sector | Weight | Value | 3M chg | 6M chg | 1Y chg |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Healthcare | 9.01% | ₹45.70 Cr | +9.09% | +9.23% | +12.51% |
| Divi's Laboratories Ltd. | Healthcare | 8.01% | ₹40.64 Cr | +3.68% | +1.92% | +7.22% |
| Torrent Pharmaceuticals Ltd. | Healthcare | 7.99% | ₹40.53 Cr | +5.27% | +4.99% | +3.27% |
| Ipca Laboratories Ltd. | Healthcare | 6.23% | ₹31.60 Cr | +5.18% | +3.95% | +2.81% |
| Lupin Ltd. | Healthcare | 5.99% | ₹30.42 Cr | +5.83% | +5.71% | +0.89% |
| Laurus Labs Ltd. | Healthcare | 5.66% | ₹28.73 Cr | +5.76% | +4.09% | +1.88% |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 5.44% | ₹27.59 Cr | +4.66% | +4.15% | +5.97% |
| Fortis Healthcare Ltd. | Healthcare | 4.50% | ₹22.85 Cr | +4.27% | +4.59% | +1.43% |
| Astrazeneca Pharma India Ltd. | Healthcare | 3.56% | ₹18.07 Cr | +4.12% | +4.07% | +2.65% |
| Glenmark Pharmaceuticals Ltd. | Healthcare | 3.42% | ₹17.36 Cr | +2.61% | — | — |
| Dr. Lal Pathlabs Ltd. | Healthcare | 3.24% | ₹16.44 Cr | +2.51% | +2.48% | +1.38% |
| Mankind Pharma Ltd. | Healthcare | 3.10% | ₹15.72 Cr | +0.03% | +1.19% | +5.82% |
| Aurobindo Pharma Ltd. | Healthcare | 3.05% | ₹15.45 Cr | +2.62% | — | +2.42% |
| Max Financial Services Ltd. | Financial | 2.43% | ₹12.35 Cr | +1.22% | — | — |
| Emcure Pharmaceuticals Ltd. | Healthcare | 2.38% | ₹12.08 Cr | +3.38% | +2.80% | — |
| Abbott India Ltd. | Healthcare | 2.29% | ₹11.63 Cr | +5.43% | +4.60% | +3.46% |
| Acutaas Chemicals Ltd. | Healthcare | 2.24% | ₹11.39 Cr | +2.07% | +1.34% | — |
| Aster DM Quality Care Ltd. | Healthcare | 2.23% | ₹11.34 Cr | +3.15% | +5.22% | +3.58% |
| Zydus Lifesciences Ltd. | Healthcare | 2.15% | ₹10.92 Cr | +1.98% | — | — |
| Concord Biotech Ltd. | Healthcare | 2.14% | ₹10.85 Cr | +1.45% | — | +2.22% |
| Ajanta Pharma Ltd. | Healthcare | 1.49% | ₹7.56 Cr | +1.61% | +2.25% | +2.89% |
| Metropolis Healthcare Ltd. | Healthcare | 1.49% | ₹7.57 Cr | +1.28% | +0.96% | — |
| Nephrocare Health Services Ltd. | Healthcare | 1.35% | ₹6.83 Cr | +1.65% | +1.31% | — |
| Manipal Health Enterprises Ltd. | Healthcare | 1.27% | ₹6.46 Cr | — | — | — |
| Others | Others | 1.22% | ₹6.16 Cr | +7.30% | +6.50% | +12.12% |
| company:20823 | Healthcare | 1.18% | ₹6.00 Cr | — | — | — |
| Dr. Reddy's Laboratories Ltd. | Healthcare | 1.14% | ₹5.77 Cr | +1.20% | +2.28% | +1.98% |
| Gland Pharma Ltd. | Healthcare | 1.14% | ₹5.77 Cr | +0.41% | +3.09% | +2.64% |
| Cipla Ltd. | Healthcare | 1.11% | ₹5.64 Cr | +1.16% | +2.15% | +5.55% |
| Medplus Health Services Ltd. | Healthcare | 0.93% | ₹4.71 Cr | +1.65% | +1.39% | +1.32% |
| Inventurus Knowledge Solutions Ltd. | Services | 0.85% | ₹4.34 Cr | +1.54% | +1.10% | — |
| company:5979 | Healthcare | 0.72% | ₹3.66 Cr | — | — | — |
| Procter & Gamble Health Ltd. | Healthcare | 0.57% | ₹2.88 Cr | +1.22% | — | — |
| company:5765 | Insurance | 0.48% | ₹2.41 Cr | — | — | — |
Sectors
Instruments
Recent changes
| Holding | From | To | Weight |
|---|---|---|---|
| Divi's Laboratories Ltd. | 6.66% | 8.01% | +1.35% |
| company:20823 | 0.00% | 1.18% | +1.18% |
| company:5979 | 0.00% | 0.72% | +0.72% |
| Torrent Pharmaceuticals Ltd. | 8.58% | 7.99% | -0.59% |
| Inventurus Knowledge Solutions Ltd. | 1.42% | 0.85% | -0.57% |
| Ipca Laboratories Ltd. | 5.72% | 6.23% | +0.51% |
| Astrazeneca Pharma India Ltd. | 4.05% | 3.56% | -0.49% |
| company:5765 | 0.00% | 0.48% | +0.48% |
| Lupin Ltd. | 6.46% | 5.99% | -0.47% |
| Laurus Labs Ltd. | 5.24% | 5.66% | +0.42% |
| Nephrocare Health Services Ltd. | 1.74% | 1.35% | -0.39% |
| Zydus Lifesciences Ltd. | 2.47% | 2.15% | -0.32% |
| Manipal Health Enterprises Ltd. | 0.96% | 1.27% | +0.31% |
| Aster DM Quality Care Ltd. | 2.53% | 2.23% | -0.30% |
| Sun Pharmaceutical Industries Ltd. | 8.82% | 9.01% | +0.19% |
| Max Financial Services Ltd. | 2.27% | 2.43% | +0.16% |
| Medplus Health Services Ltd. | 1.09% | 0.93% | -0.16% |
| Abbott India Ltd. | 2.41% | 2.29% | -0.12% |
| Dr. Lal Pathlabs Ltd. | 3.12% | 3.24% | +0.12% |
| Apollo Hospitals Enterprise Ltd. | 5.35% | 5.44% | +0.09% |
| Acutaas Chemicals Ltd. | 2.15% | 2.24% | +0.09% |
| Concord Biotech Ltd. | 2.05% | 2.14% | +0.09% |
| Ajanta Pharma Ltd. | 1.40% | 1.49% | +0.09% |
| Emcure Pharmaceuticals Ltd. | 2.46% | 2.38% | -0.08% |
| Procter & Gamble Health Ltd. | 0.64% | 0.57% | -0.07% |
| Gland Pharma Ltd. | 1.20% | 1.14% | -0.06% |
| Fortis Healthcare Ltd. | 4.55% | 4.50% | -0.05% |
| Others | 0.98% | 1.02% | +0.04% |
| Metropolis Healthcare Ltd. | 1.46% | 1.49% | +0.03% |
| Dr. Reddy's Laboratories Ltd. | 1.11% | 1.14% | +0.03% |
| Glenmark Pharmaceuticals Ltd. | 3.44% | 3.42% | -0.02% |
| Cipla Ltd. | 1.13% | 1.11% | -0.02% |
| Mankind Pharma Ltd. | 3.09% | 3.10% | +0.01% |
| Aurobindo Pharma Ltd. | 3.04% | 3.05% | +0.01% |
Compare
Similar funds
The rest of the category, so this fund’s numbers have something to sit against.
| Fund | AUM | Expense | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| Category average | ₹3,579 Cr | 2.19% | 27.3% | 17.7% | 20.1% |
 ICICI Prudential Healthcare Fund | ₹6,996 Cr | 2.07% | 14.5% | 14.2% | 19.4% |
 SBI Healthcare Opportunities Fund | ₹5,796 Cr | 1.99% | 33.1% | 19.9% | 22.2% |
 Mirae Asset Healthcare Fund | ₹3,555 Cr | 2.03% | 29.9% | 18.4% | 19.7% |
 UTI Healthcare Fund | ₹1,444 Cr | 2.21% | 30.4% | 19.1% | 21.1% |
 LIC MF Healthcare Fund | ₹103 Cr | 2.67% | 28.7% | 16.9% | 17.9% |
About
About this fund
The scheme’s own words, its benchmark and the people running it.
Investment objective
The scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns.
Fund managers
- Ankeet PandyaMBA FinancePrior to joining Baroda BNP Paribas Mutual Fund, he was working with InCred Asset management Private Ltd, Motilal Oswal Securities Ltd and Elara Capital India Private Ltd.
- Rohan KordeMr. Korde is a Masters in Management Studies (Finance), Bachelor of CommercePrior to joining Baroda BNP Paribas Mutual Fund, he has worked with ITI Mutual Fund, BOB Capital Markets as Vice President
Tools
Return calculator
What ₹10,000 a month in this fund would have grown to over each period, based on its past returns.
| Over the past | Total investment | Would’ve become | Growth | Returns |
|---|---|---|---|---|
| 6 months16.77% absolute | ₹60,000 | ₹70,062 | 16.77% | |
| 1 year13.71% annualised | ₹1,20,000 | ₹1,29,296 | 7.75% |
Returns for 1 year and longer are annualised (CAGR); 6-month figures are absolute. Past returns are not a forecast.
How this is calculated
Each monthly instalment grows at the fund’s annualised return ÷ 12 per month until the end of the period, the same formula as our SIP calculator.
The amount compounds once a year at the fund’s CAGR for that period, the same formula as our lumpsum calculator.
Questions
Frequently asked questions
The things people ask about this scheme.